Abstract
Intra Peritoneal Chemo Hyperthermia (IPCH) with Mitomycin C (MMC) or Cisplatinum (CP) was used to treat 32 patients with far advanced digestive or ovarian cancers and peritoneal carcinoma tosis. Surgical resection of the primary tumor has been possible in 18 cases. After closure of the abdominal wall, a 90 minutes IPCH was performed under general anaesthesia and 32 °C general hypothermia, through 3 intraperitoneal drainages realizing a closed circuit, using 10 mg/1 of MMC or 15 to 25 mg/1 of CP in 6 1 of peritoneal diaiysate heated at the inflow temperature of 46 to 49 °C. The mortality rate was 3% and the morbidity rate was 3%. In 11 out of 12 patients with preoperative malignant ascites, no more ascites could be found after IPCH. For peritoneal carcinomatosis from digestive origin, median survival was 11.2 months and 1 year survival rate was 46.9 %. These encouraging preliminary results show that IPCH is a safe and reliable treatment for peritoneal carcinomatosis in far advanced digestive or ovarian cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chu D Z, Lang N P, Thompson C, Osteen P R, Westbrook K C: Peritoneal carcinomatosis in nongynecologic malignancy.Cancer 63, 364–367 (1989).
Torisu M, Katano M, Kimura Y, Itoh H, Taresue M: New approach to management of malignant ascitis with a strep-tococcal reparation OK-432: Improvement of host immunity and prolongation of survival.Surgery 93, 357–364 (1983).
Hagiwara A, Taakahashi T, Lee R, Ueda T, Tareda M, Itoh H: Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycine C absorbated on activated carbon particles.Cancer 59, 43–49 (1987).
Breasted J H: The Edwin Smith Surgical Papyrus, in Licht S (ed.):Therapeutic heat and cold, pp.196–211, 2nd edn.. Baltimore, Waverly (1930).
Crile G: The effect of heat and radiation on cancers implanted on the feet of mice.Cancer Res 23, 372–380 (1963),
Overgaard K, Overgaard J: Investigations on the possibility of a thermic tumor therapy.Eur J Cancer 8, 65–78 (1972).
Hahn G M: Potential for therapy of drugs and hyperthermia.Cancer Res 39, 2264–2268 (1979).
Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y: Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with anticancer drug.Cancer Res 44, 1840–1842 (1984).
Fujimoto S, Shrestha R D, Kokubun M,et al.: Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seed ings.Ann Surg 208, 36–41 (1988).
Gilly F N, Carry P Y, Sayag A C,et al.: Intraperitoneal chemohyperthermia with Mitomycine C in dogs: General, biological and anastomotic tolerance.Int J Hyperthennia 8, 5, 659–666 (1992).
Hahn G M: Metabolic aspects of the role of hyperthermia in mammalian cell inactivation and their possible relevance to cancer treatment.Cancer Res 34, 3117–3123 (1974).
Streffer C, Tamulevicius P, Schmidt K: Poly (ADPR) synthetase activity in melanoma cells after hyperthermia and radiation.Radiat Res 94, 589–590 (1983).
Barlogie B, Corry P M, Drewinko B:In vitro thermo-chemotherapy of human colon cancer cells with cipdichlo-rodiamineplatinium.Cancer Rep 40, 1165–1168 (1980).
Teicher B A, Kowal C D, Kennedy K A, Sartorelli A C: Enhancement by hyperthermiaof thein vitro cytotoxicity of mitomycin C toward hypoxic tumor cells.Cancer Res 41, 1096–1099 (1981).
Pettigrew R T, Galt J M, Ludgate C M, Home D B, Smith A N: Clinical effects of whole body hyperthermia in advanced malignancy.Br J Surg 61, 727–731 (1974).
Cosset J M, Bichler K H, Strohmaier W L,et al.: In Gautherie M (ed.): Interstitial, endocavitary and perfusional hyperthermia methods and clinical trials. Berlin, Springer Verlag (1990).
Spratt J S, Edwards M, Kubota T, Linberg R, Tseng M T: Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management.Curr Prob Cancer 10, 558–584 (1986).
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T: Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.Cancer 61, 232–237 (1988).
Fujimura T, Yonemura Y, Fuschida S,et al.: Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second look operation.Cancer 65, 65–71 (1990).
Fujimoto S, Shrestha R D, Kokubun M,et al.: Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer.Cancer 64, 154–160 (1989).
Fujimoto S, Kokubun M, Shestra R D,et al.: Prevention of scald injury on the peritoneo-serosal surface in advanced gastric cancer patients treated with intraperitoneal hyperthermic perfusion.Int J Hyperthermia 7, 543–550 (1991).
Gilly F N, Sayag A C, Carry P Y, Braillon G, James I, Voloch A, Penteix G: Intra peritoneal chemo hyperthermia: a new therapy in the treatment of peritoneal seedings. Preliminary report,Int Surg 76, 164–167 (1991).
Yonemura Y, Fujimura T, Fuscida S,et al.: Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination.World J Surg 15, 530–536 (1991).
Kaibara N, Hamazoe R, Iitsuka Y, Maeta M, Koga S: Hyperthermic peritoneal perfusion combined with anti-cancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer.Hepato Gastroenterol 36, 75–78 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilly, F.N., Carry, P.Y., Bracket, A. et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol. & Tumor Pharmacother. 9, 177–181 (1992). https://doi.org/10.1007/BF02987754
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02987754